Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
about
Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strainsWhy the Cochrane Risk of Bias Tool Should Include Funding Source as a Standard ItemCOX-2 inhibitors: a CLASS act or Just VIGORously promotedRisk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysisComparison of descriptions of allocation concealment in trial protocols and the published reports: cohort studyCOX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patientsPrescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control studyEfficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.Adverse drug reaction updateAssessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tractCurrent approaches to prevent NSAID-induced gastropathy--COX selectivity and beyondAn economic model of long-term use of celecoxib in patients with osteoarthritisBuilding a better aspirin: gaseous solutions to a century-old problemTrial publication after registration in ClinicalTrials.Gov: a cross-sectional analysisWhy we need easy access to all data from all clinical trials and how to accomplish itNSAIDs.US Food and Drug Administration gets it rightSystematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity.cPLA2 is protective against COX inhibitor-induced intestinal damage.Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugsRisk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia.Do coxibs reduce prescription of gastroprotective agents? Results of a record linkage study.Principles for evidence-based drug formulary policy.The double-edged sword of COX-2 selective NSAIDsReview article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits.Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trialLumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxibNon-surgical treatment of osteoarthritis: a half century of "advances".Analgesia for patients with advanced disease: 2An evidence-based update on nonsteroidal anti-inflammatory drugs.Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs.Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports.The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in ScotlandCyclooxygenase-2 inhibitors: do they have a role in emergency department prescribing?Celecoxib pathways: pharmacokinetics and pharmacodynamics.Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.
P2860
Q21559453-72DE7D48-C6E0-4928-A672-C88E2E69FE8FQ24201550-5E83AB12-C369-4929-AC1D-D0838F2B49D0Q24529085-B9D8CBAC-C916-497B-846E-EB88258C161EQ24555478-CF8A462E-F646-4952-8F2F-8089E3CC9B02Q24555653-6EE70067-4549-4E9B-9A3B-A52B178F0167Q24796193-BFB1D31B-2682-4C25-A588-A0D966BAB055Q24803974-5E0E5CDF-8F1C-4258-9A2A-6CA511470799Q28193800-3EB600F5-AAA7-4BA0-A477-3EF97721BDB7Q28193830-7AF07984-9DB2-491F-AEC3-6B2B3DB827F9Q28196933-0D99B957-E39C-4D62-9008-23874326169DQ28210656-0BBA7115-FD76-48DB-AEE5-84B10FA41F92Q28218005-09DE2490-309C-4D52-8806-452F349129BDQ28218664-29CF5533-C327-4C15-BA9D-D9A0F1DED747Q28476002-EAB8E1B5-2A93-44C0-8AF0-6F48FE210518Q28732492-3BC74D3D-538F-48D7-860A-270AF1724C6CQ33448171-7FCFA923-590B-4C0F-9E4C-D624B7596A65Q33812256-7A35AA83-24B7-4509-8468-D11CF69B339BQ33813806-88619D64-AAF7-49C4-9782-8E376FBFF694Q34072006-6C00FCD0-0647-43BD-B379-9795E8B54674Q34093824-86DAAAC6-BBB8-44A1-90B2-02ADC2CD57D6Q34165468-1EA25F7D-B8B0-4ECE-9A63-2FC690B76E21Q34245387-9BC7DF2A-B33B-4753-8522-6EDAFCA4CD46Q34305332-D08A87FC-A266-4C89-99CC-2112A412D45FQ34666402-70ED1B15-CD41-4F51-852A-E425F9FFCF8FQ34724227-6E85287C-2286-4B4F-AD33-57EF68577EDFQ34994656-903DD98C-2245-463C-B6E8-F075962806EDQ35058190-5BD87562-FAED-4CFC-ADA7-66B32CB60FC2Q35083808-A20C2878-5BD8-4D84-9682-F79C6CADFD05Q35108309-A6614D82-47B0-4C17-8A6B-4E799AC02D45Q35520722-27D4AD7C-A193-4D4C-8050-3DAC229CC682Q35553447-10F24D62-05EE-4E49-8F39-58D9D936CF31Q35553761-9A124DF2-7F80-4C7F-985E-5B2930BD68BAQ35745100-6D413830-5FB9-4E99-B917-985FF21A3137Q35758411-28C9B430-7EF5-42A2-A654-A842DAE51B78Q35814862-D437638D-C4FD-4DDB-A561-BE37399586DAQ35824111-DA2160C5-C298-4097-8188-CF459ED980DFQ35827761-F75BE89B-2BC6-487E-818A-0CDE5097F052Q35828904-E16359EB-5103-4F62-A9C8-90DA216EBB9EQ35830941-EA4B58BB-53CB-443A-A0B5-973B8F9AC208Q35873867-ADE0AEC7-B87D-4C9A-B14D-A88242B36806
P2860
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Are selective COX 2 inhibitors ...... oidal anti-inflammatory drugs?
@en
Are selective COX 2 inhibitors ...... oidal anti-inflammatory drugs?
@nl
type
label
Are selective COX 2 inhibitors ...... oidal anti-inflammatory drugs?
@en
Are selective COX 2 inhibitors ...... oidal anti-inflammatory drugs?
@nl
prefLabel
Are selective COX 2 inhibitors ...... oidal anti-inflammatory drugs?
@en
Are selective COX 2 inhibitors ...... oidal anti-inflammatory drugs?
@nl
P2860
P1433
P1476
Are selective COX 2 inhibitors ...... oidal anti-inflammatory drugs?
@en
P2093
Anne W S Rutjes
Paul A Dieppe
P2860
P304
P356
10.1136/BMJ.324.7349.1287
P407
P50
P577
2002-06-01T00:00:00Z